Towards cancer-aware life-history modelling by Kokko, Hanna & Hochberg, Michael
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Towards cancer-aware life-history modelling
Kokko, Hanna; Hochberg, Michael
Abstract: Studies of body size evolution, and life-history theory in general, are conducted without taking
into account cancer as a factor that can end an organism’s reproductive lifespan. This reflects a tacit
assumption that predation, parasitism and starvation are of overriding importance in the wild. We argue
here that even if deaths directly attributable to cancer are a rarity in studies of natural populations, it
remains incorrect to infer that cancer has not been of importance in shaping observed life histories. We
present first steps towards a cancer-aware life history theory, by quantifying the decrease in the length of
the expected reproductively active lifespan that follows from an attempt to grow larger than conspecific
competitors. If all else is equal, a larger organism is more likely to develop cancer, but, importantly, many
factors are unlikely to be equal. Variations in extrinsic mortality as well as in the pace of life — larger
organisms are often near the slow end of the fast-slow life history continuum — can make realized cancer
incidences more equal across species than what would be observed in the absence of adaptive responses to
cancer risk (alleviating the socalled Peto’s paradox). We also discuss reasons why patterns across species
can differ from within-species predictions. Even if natural selection diminishes cancer susceptibility
differences between a species, within-species differences can remain. In many sexually dimorphic cases
we predict males to be more cancer-prone than females, forming an understudied component of sexual
conflict.
DOI: 10.1098/rstb.2014.0234
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-115283
Published Version
 
 
Originally published at:
Kokko, Hanna; Hochberg, Michael (2015). Towards cancer-aware life-history modelling. Philosophi-
cal Transactions of the Royal Society of London. Series B: Biological Sciences, 370:20140234. DOI:
10.1098/rstb.2014.0234
rstb.royalsocietypublishing.org
Research
Cite this article: Kokko H, Hochberg ME.
2015 Towards cancer-aware life-history
modelling. Phil. Trans. R. Soc. B 370:
20140234.
http://dx.doi.org/10.1098/rstb.2014.0234
Accepted: 14 April 2015
One contribution of 18 to a theme issue
‘Cancer across life: Peto’s paradox and the
promise of comparative oncology’.
Subject Areas:
evolution
Keywords:
Peto0s paradox, cancer, life history,
body size, sexual conflict, coevolution
Authors for correspondence:
Hanna Kokko
e-mail: hanna.kokko@ieu.uzh.ch
Michael E. Hochberg
e-mail: mhochber@univ-montp2.fr
Towards cancer-aware life-history
modelling
Hanna Kokko1,2 and Michael E. Hochberg1,3,4
1Wissenschaftskolleg zu Berlin, Institute for Advanced Study, Wallotstrasse 19, Berlin 14193, Germany
2Institute of Evolutionary Biology and Environmental Studies, University of Zurich, Winterthurerstrasse 190,
Zurich 8057, Switzerland
3Institut des Sciences de l’Evolution, Universite´ Montpellier, UMR5554 du CNRS, Montpellier 34095, France
4Santa Fe Institute, 1399 Hyde Park Road, Santa Fe, NM 87501, USA
Studies of body size evolution, and life-history theory in general, are conduct-
ed without taking into account cancer as a factor that can end an organism’s
reproductive lifespan. This reflects a tacit assumption that predation, parasit-
ism and starvation are of overriding importance in the wild. We argue here
that even if deaths directly attributable to cancer are a rarity in studies of natur-
al populations, it remains incorrect to infer that cancer has not been of
importance in shaping observed life histories. We present first steps towards
a cancer-aware life-history theory, by quantifying the decrease in the length
of the expected reproductively active lifespan that follows from an attempt
to grow larger than conspecific competitors. If all else is equal, a larger organ-
ism is more likely to develop cancer, but, importantly, many factors are
unlikely to be equal. Variations in extrinsic mortality as well as in the pace
of life—larger organisms are often near the slow end of the fast–slow life-
history continuum—can make realized cancer incidences more equal across
species than what would be observed in the absence of adaptive responses
to cancer risk (alleviating the so-called Peto’s paradox). We also discuss
reasonswhy patterns across species can differ fromwithin-species predictions.
Even if natural selection diminishes cancer susceptibility differences between
species, within-species differences can remain. In many sexually dimorphic
cases, we predict males to be more cancer-prone than females, forming an
understudied component of sexual conflict.
1. Introduction
Animal body size is a key life-history trait in terms of the ecological niche and the
associated evolutionary process [1,2]. Body size affects the ability to survive and
reproduce via a diversity of mechanisms including competition for limiting
resources and for mating opportunities, and predation avoidance [3,4]. Life-
history theory also has to explain ‘what keeps organisms small’ (despite often
documentable benefits of being larger), with studies indicating the roles of natural
enemies and disease [5,6], and reviews focusing on costs of large size such as
delayed reproduction and high energy requirements during or after growth
[7,8]. Here we focus on an underappreciated cost: because growing to a larger
body size requiresmore cell divisions (this is a simple corollary of the fact that ani-
mals vary much more in cell number than cell size), it is difficult to build a larger
body without elevating the cancer risk experienced by the organism.
Most of what is known about the biology of cancer risk is based on experi-
mental cell cultures, laboratory mice and correlative evidence found in human
populations. Evolutionary ecologists rarely include cancer in their lists of
sources of mortality for non-domesticated animals, which reflects a tacit
assumption that parasites, predation and starvation are of overriding import-
ance in the wild. We argue that this is an oversimplification because cancer,
even if rarely directly observable as a cause of death, can have significant evo-
lutionary implications [9]. This is for two reasons. First, whether or not a species
& 2015 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
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is cancer-prone, fieldmethods are unlikely to revealmuchmor-
tality directly attributable to cancer—as long as we make the
sensible assumption that suboptimal physical performance of
an animal (due to an incipient tumour or any other disease)
will make it an easier target for predators or parasites. Conse-
quently, for organisms living in thewild, cancer-related deaths
would typically be attributed to other, more direct causes, long
before a tumour is visible (the spectacular contagious tumours
of Tasmanian devils being an obvious exception). A second
line of evidence that cancer risk is being moulded by natur-
al selection comes from the so-called Peto’s paradox. This
paradox is the lack of a statistically significant association
between cancer risk and body size or longevity across species
[10–12], despite reasoning based on first principles (assum-
ing constant risk per cell division) predicting that a positive
association should exist [13].
The details of the prediction that larger, longer-lived organ-
isms should, all else being equal, bemore vulnerable to cancers
are based on two interrelated phenomena: standing cells as
‘targets’ for mutagenesis (viruses, UV, etc.) and the vulner-
ability of cell replication to random mutation [14,15]. In an
intraspecific context, there is good evidence that this vulner-
ability is heightened for entities—either tissues or whole
organisms—that are larger than their peers. In the context of
different tissues, Tomasetti & Vogelstein [16] recently showed
that the total number of healthy stem cell replications over a
lifetime in humans explained a significant amount of variation
in incidence among 31 cancer types. The authors suggest that
random mutations occurring at cell division is a mechanism
that could explain this effect (but see [15,17]). In a similar
vein, at the whole organism level, height predicts the risk of
some cancers, especially bone cancers, in humans [16–21]
(but see [22]). There is also evidence for higher cancer incidence
in larger dog breeds and giant laboratory mice [21,23].
These results projected onto interspecific patterns suggest
that evolution towards larger body sizes will increase cancer
vulnerability, unless some lifestyle, physiological or cellular
mechanism evolves that limits increases in cancer risk [10,11].
One possible mechanism that influences risk is that larger
species tend to have a slower pace of life (they occur at the
slow end of the so-called fast–slow continuum, e.g. [24,25];
see [26] for a cellular-level view). However, the association
between large bodies and slow lives is a double-edged
sword. If cells replicate at a slower rate, the organism will on
the one hand experience less oncogenetic risk per time unit,
but on the other hand, a slow-paced organism has to maintain
its body for a longer amount of absolute time to achieve any
reproductive success. As a whole, therefore, it remains the
case that the larger number of cell divisions required to build
a large body creates cancer risks that larger-bodied organisms
need to cope with. Peto’s paradox suggests that solutions have
been found [11], and the same message arises in a recent study
among tissues in humans: Noble et al.’s reanalysis [15] of the
Tomasetti & Vogelstein dataset [16] reveals that cancer inci-
dence saturates with the total number of stem cell divisions.
This is suggestive of a role of natural selection either in limiting
the size or stem cell replications in the most cancer-prone tis-
sues and/or in lowering the probability of obtaining cancer
through specific mechanisms in these same tissues.
Given the diversity and complex interlocking of different
life-history traits, and their ecological and evolutionary
interactions with carcinogenesis, deciphering simple causal
pathways is likely to be challenging. Here we employ a
simple mathematical argument to investigate how we should
expect body size to relate to cancer risk in different environ-
mental settings. First, in §2, we consider how different
empirical representations of cancer ‘risk’ can be encapsulated
into a mathematical function. With this in hand, we then
develop and analyse mathematical models to address two
questions: does cancer risk constrain body size evolution (§3),
and conversely, when do we expect selection for improved
cancer defences (§4)? Finally, in §5, we compare our model
and results with previous theoretical studies and in §6 discuss
limitations and future directions.
2. Towards ‘cancer-aware’ life-history modelling
Absolute cancer risk (hereafter ‘cancer risk’) is the probability
that a person contracts the disease over a fixed period of time,
usually for a range of specific ages or over a lifetime. Cancer
risk is generally calculated from epidemiological data, but
how could it be mechanistically modelled?
There are various suggestions in the literature [27] as well
as recent empirical evidence [16] that, in humans, cancer risk
scales straightforwardlywith the total number of cell divisions.
A linear fit to the full dataset in Tomasetti & Vogelstein [16]
gives: 1011 divisions! approximately 10–1 lifetime risk; 107
divisions! 10–4 lifetime risk. On a log–log scale one could
derive a simple prediction that if increasing body size by a
factor of 10 requires 10 times as many cell divisions (an
assumption that we shall discuss in §5), then each magnitude
of body size increase should lead to 103/4 ¼ 5.6-fold cancer
risk. It also follows that body sizes beyond approximately
1012 stem cells should not exist in nature, as cancer risk
would then reach 100%. (A human being is estimated to con-
tain 3.72  1013 cells [28], but not all of these are obviously
stem cells.) However, incidences in Tomasetti andVogelstein’s
dataset begin to saturate in tissues beyond approximately 109
total cell divisions, suggesting either that natural selection
has resulted in these tissues being differentially protected
from cancer, and/or constrained in size and/or other mortal-
ities occur before cancer, meaning lower effective cancer
incidence [15]. Noble et al. [15] additionally showed that
when considering families of tissues, their slopeswere approxi-
mately unity, further indicating that natural selection can
explain the overall pattern.
The above human-centred discussion would create the
wrong predictions in an interspecific comparison, for example,
by ignoring all selective processes that may have occurred to
make interspecific cancer incidences more equal than they
would be based on cell counts alone.A perhapsmore important
shortcoming is that ‘risk’ without reference to lifespan does not
make much sense in an across-species context. In other words,
while it makes sense to quantify a lifetime risk for a human
population where each member has roughly the same expected
lifespan (in the absence of any specific cancer), an attempt to
encapsulate the idea of risk with a single number across organ-
isms with markedly different lifespans would lead to a biased
view of the problem. Consider a hypothetical cancer that an
organism cannot avoid, in the sense that its incidence is
almost 100% by the age of 2 years. If the organism is a free-
living mouse, it may well have reproduced and also died of
other causes by this time; if it is an elephant, it would not be
anywhere near maturity by the time its life was cut short by
cancer. For this reason, we derive, below, explicit cumulative
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probabilities for cancer that is specified for each age, t, of the
animal, rather than a single number for risk.
We also consider the mortality rate that is associated with
causes of death other than cancer (extrinsic mortality,
denoted m). Empirical data indicate that age-specific patterns
show very wide variation [29] and thus we simply assume a
constant mortality rate over time. If the extrinsic mortality
rate is m, then the expected lifespan (in the absence of
cancer) is L ¼ 1/m.
A life-history model will also have to assume a schedule
of reproduction. In nature, there is an astounding diversity
of such scheduling [29], from age-related increases in repro-
ductive success to declines. To avoid biasing our attention
towards extreme patterns (that might only apply in specific
taxa), we take the middle ground position: we assume that
reproductive success neither increases nor decreases with
age; instead we assume a constant rate of reproductive
success that accumulates throughout life as long as the indi-
vidual is cancer-free. In organisms that live for several
years, this would imply that each additional year of life is
assumed to add equally much reproductive success as any
of the earlier ones, but we also intend our model to apply
to shorter lived organisms (where lifespans are mere fractions
of years). Our model, therefore, uses continuous time, where
lifespan calculations are equally valid whether lifespan falls
below or remains above the value of one unit of time.
Our steps towards a ‘cancer-aware’ life-history model
use a simplified version of eqn (2) in [30] (see [10,31] for its
original derivations)
B(t) ¼ 1 (1 (1 ekt)n)N :
The quantity B(t) (examples plotted in figure 1a–c) gives
the probability that an organism has cancer by time t
(where t ¼ 0 is the time point of fertilization). Here, k is the
rate of a single lineage undergoing one rate-limiting step
towards the multi-stage process of carcinogenesis, expressed
e.g. in steps occurring per year. We assume that the organism
ends its reproductive career if n rate-limiting steps have hap-
pened in any of its N cell lineages—i.e. it has cancer. We
assume that while the cancer may not have ended its life
yet, realized reproductive success is zero from this time
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Figure 1. (a– c) B(t), the cumulative probability (conditional on the individual being alive) that cancer has occurred in at least one of the N cell lineages, as a
function of age t, when n ¼ 4 and k ¼ 10– 4 unless indicated differently in the figure. In each example, the blue curve has better cancer defences than the red
curve, either because (a,b) its k is lower, or (c) because there is an additional defence mechanism that increases the number of rate-limiting steps from n ¼ 4 to
n ¼ 5. (d– f ) The life-history consequences of (a– c), assuming a constant extrinsic mortality rate of m ¼ 0.1: the proportion of individuals alive (dashed lines)
would decrease linearly in a log-scale plot if there was no cancer; the downcurving from linearity indicates the effects of cancer. The numbers give the expected
lifespan, which would be L ¼ 10 in the complete absence of cancer. Solid curves give the probability, for each age t, that cancer is the cause whenever a repro-
ductive career ends at that t. Dotted line style is used when fewer than 1% of individuals are alive from that t onwards, and we do not plot the curve beyond fewer
than 0.1% being alive; this helps to emphasize that most individuals end their lives during a stage where cancer’s role is increasing, but the overall incidence may
remain low throughout in some cases, e.g. in (e) where we assume a small body size N.
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onwards. We also assume that cancers occurring during the
growth (rather than maintenance) phase of an organism can
be neglected; hence N is assumed constant (see §5).
We interpret k to combine the rate of a cell dividingwith the
probability of the rate-limiting step (mutation leading to
cancer) happening. For example, Calabrese & Shibata [27]
give the per-division estimate 10–6 for a specific gene target,
and one division every 4 days; thiswould give a rough estimate
of 365/4  10–6  10–4 steps per year for our k (note that
our notation differs from theirs, as our model structure is
somewhat different; in §5 we shall also consider how the
growth phase and the maintenance phase of an organism
may complicate the issue).
Wehave 12 e2ktas theprobability that a single rate-limiting
step has already happened by time t, and 12(12 e2kt)n the
probability that not all steps have happened yet in the same
focal cell lineage. Note that k will be lower for organisms with
a slow ‘pace of life’ (few cell divisions per unit time), but an
organism might also be able to reduce k without reductions in
cell division rate if it has better defences against cancer,
e.g. mechanisms to recognize and kill tumour cells, or ‘smart’
morphological arrangements such as that found in the gut epi-
thelium (see discussion in [14]: because of being the site of
digestive fluid production, cells here have to be continually
replaced and the risk created by the unavoidably fast cell repli-
cation rate appears to be minimized by morphology that
mechanistically forces cells to flow unidirectionally from phys-
ically separate crypts into the gut via villi—meaning that any
abnormalities cannot easily spread into neighbouring crypts
before they are simply digested away).
The above equation as awhole takes the probability that all
N lineages are healthy so far, (12(12 e2kt)n), and forms its
complement to yield the probability B(t), of cancer having
already emerged in at least one cell lineage, as indicated above.
Figure 1a–c shows examples of the behaviour of B(t) over
time. Reducing k by 50% doubles the time (see arrows in
figure 1a) it takes for cumulative cancer risk to reach any pre-
specified value; reducing k by 75% would quadruple the
time (since 1/(1–0.75)¼ 4), and so on. In absolute time, the
delay is longer if the organism has already reached sufficiently
old age for cancer to be a significant risk (the arrows are longer
the nearer they are drawn to the upper end of the curves in
figure 1a). Consequently, at young age, the curves depict-
ing the proportion of individuals still alive (dashed lines in
figure 1d– f) are nearly linear on a log scale: here extrinsic mor-
tality (which we assume to operate age-independently)
removes far more individuals than cancer from the pool of
reproductively active individuals. The more the curves deviate
downwards from linearity, the more individuals have been
removed due to cancer. The numbers associating with these
curves in figure 1d– f indicate expected lifespan, with all
causes of death combined. These numbers are obtained by
integrating A(t)(1–B(t)), where A(t) is the probability that
the organism has avoided death by extrinsic mortality
(A(t) ¼ e–mt) for t time units (in figure 1, we assume m ¼ 0.1,
such that average lifespan would reach L ¼ 10 if cancer was
not an issue). Figure 1d– f also gives the age-dependent prob-
ability that cancer (rather than extrinsic mortality) is the
cause of a reproductive career ending at time t.
It is useful to comment on the differences between the
different examples in figure 1. In figure 1(a,d ), we assume a
rather large organism that could in principle live (on average)
10 years. Cancer does significantly reduce its lifespan, and
better mechanisms to delay its onset (the difference between
the red and the blue curves) would lead to a strong improve-
ment of lifespan from 7.8 to 9.4 years (figure 1d ). However, if
such mechanisms are not available, a smaller but still decid-
edly non-negligible increase—from the original 7.8 in figure
1a to 8.3 years in figure 1b—can be achieved if the organism
simply does not grow as large. One interesting interpretation
is that the different curves could relate to different sexes in
sexually size dimorphic species. If females are smaller
(figure 1b) than males (figure 1a), then they might escape
cancer more often even if the defences against cancer were
equally strong (same-coloured curves in figure 1).
The effect of body size potentially dramatically changing
the role of cancer in life-history evolution is most visible in
figure 1c. Here we have changed n (rather than k) to reflect a
potentially very efficientway to delay cancer: here an organism
has evolved to increase the number of rate-limiting steps that
need to occur before cancer can occur (this additional control
mechanism itself needs to be ‘broken’ before cancer can
occur; see [10,11] for discussion and evidence). While cancer
is now very efficiently delayed (figure 1c), we here also simul-
taneously assume that the organism is one magnitude smaller
than the individuals of figure 1a. For this reason, cancer
remains a limited problem (lifespan 9.21 was reached) even if
the additional control is not in place.
To proceed beyond isolated examples, we now ask two
questions:
(1) Does cancer risk constrain body size evolution? For an
organism with parameters m, k, n and N, how costly (in
terms of the proportion of expected reproductively active
lifespan lost) is it to have a specified, say 10%, increase in
body size? We assume that ‘all else is equal’, that is
(i) the organism attempts to increase N without reducing
k via a slower pace of life or better cancer defences, and
(ii) extrinsic mortality m remains constant. Note that
within a species, extrinsic mortality can either increase
with body size, e.g. because increasing growth rate
beyond an optimum makes individuals more vulnerable
to food shortages [7], or decrease with body size, should
the individual grow beyond the size range of some of its
potential predators. Across species, evidence points to
slower scheduling of life (longer lifespans and generation
times) with increasing body size [32], suggesting that a
decrease is the general pattern.
(2) When do we expect selection for improved cancer
defences? For an organism with parameters m, k, n and
N, how large is the potential benefit of improved cancer
defences in terms of increased reproductively active life-
span? In other words, if k is reduced by, say, 10%, or n is
increased, how much longer will the organism live?
Figure 2 exemplifies the answers using n ¼ 3 and k ¼ 10–4
(alternative values give generally similar shapes). We will
consider each of the two questions in turn.
3. Does cancer risk constrain body size
evolution?
In figure 1, we used relatively large differences in body size to
form our examples: interpreting a change from figure 1b to 1a
as a 100% increase in body size, the corresponding changes in
expected lifespan are 8.30! 7.79 (a 6% decline) or 9.61!
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9.40 (a 2% decline). This illustrates two insights (i) there is
clearly not a universal, fixed ratio describing how dangerous
in terms of cancer risk it is to grow larger; but (ii) these risks
can be significant: a several per cent reduction in expected
lifespan is not trivial.
In figure 2a, which investigates a much larger parameter
range than figure 1, we explore the generality of these insights.
To make the comparisons relevant for micro-evolutionary
change and/or intraspecific differences (e.g.males and females
of a size dimorphic species), we investigate howamoremodest
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Figure 2. (a) Cost, expressed as the proportion of lifespan lost, of growing 10% larger than the baseline; (b) benefit, expressed as the proportional increase in
expected lifespan, of reducing k (the rate at which each cell lineage undergoes rate-limiting steps towards cancer) by 10%; (c) benefit, again expressed as the
proportional increase in expected lifespan, of increasing n by one step (to n ¼ 4). Baseline parameters are k ¼ 10– 4, n ¼ 3, m ¼ 1/L with L as indicated on the
y-axis, and N as indicated on the x-axis. To interpret values, e.g. L ¼ 10 combined with a cost of 0.02 means that such an organism will shorten its expected
lifespan from 10 years to (1–0.02)  10 ¼ 9.8 years—all else being equal losing an expected 2% of its reproductive success—if it grows 10% larger from its
baseline of N cells.
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change in body size (10% larger) translates to a shorter
expected lifespan, but do this for a much larger range of
body size values than in figure 1; we also vary extrinsic mor-
tality widely to yield different values of L ¼ 1/m, which is
the expected lifespan an organism would reach if defences
against cancer were perfect.
To interpret figure 2a, it is important to understand where
a small-bodied versus a large-bodied organism is likely to be
located with respect to the two horizontal axes L and N. The
axis reflecting the number of cells, N, is clear: it takes more
cells (and cell divisions) to grow to a large size than to a
small size, and as such figure 2a shows that large organisms,
for a given k, n and m (the ‘all else is equal’ assumption), will
risk a much larger proportional reduction in expected repro-
ductively active lifespan than will small organisms. With the
numerical values of figure 2a, the reduction (the cancer risk
cost) is, maximally, 3.3% of lifespan lost for a 10% increase
of body size.
How easy is it for an individual to benefit from increased
body size despite the cost? The benefits of being large are
obviously strongly system dependent, and they can also
depend on the individual’s sex [33]. Assuming, as we do,
that reproductive success accrues throughout cancer-free life,
then an individual who lives a 3.3% shorter life should enjoy
increased reproductive success of 1/(1–0.033) ¼ 1.035-fold,
per time unit, compared to its smaller peers; if this magnitude
(or higher) of a reproductive benefit exists, then the heightened
cancer risk will not prevent net selection from favouring larger
individuals. We consider these percentages to represent bio-
logically achievable values, given that larger individuals may
have better access to food and other resources, including
(for males) access to females. In species with a polygynous
mating system where body size is a significant predictor of
outcompeting conspecifics, rewards of being somewhat
larger than conspecifics could be much larger than a few per
cent. It follows that individuals, especially males in sexually
dimorphic species, may evolve in a direction that increases
the incidence of cancer.
On the other hand, the result also means that body size evo-
lution can be associated with a substantial cost of reduced
lifespan due to cancer (despite the fact that most causes of
death may remain non-cancer related). If there are other costs
of being large [7], then cancer risk may well tip the balance
from further increases being favoured to being counter-selected.
In reality, ‘all else is not equal’ with respect to at least two
parameters: m and k. The effect of extrinsic mortality m is visible
along the L-axis (L ¼ 1/m gives the expected lifespan were the
individual able to avoid all cancers). Given that lifespans gener-
ally increasewith body size [32,34], large-bodied organisms are
generally at the high end of both theN- and L-axes. This is pre-
cisely the region where the cancer-risk costs of increasing body
size are significant. In other words, if an individual is already
large and long-lived (slow life history), becoming larger still
is much costlier than a similar percentage increase at the fast
end (small and short lived) of the life-history spectrum.
The effect of k is not directly visible in figure 2a, but
repeating the calculation for a lower value of k leads to a
figure with smaller costs (not shown). This is logical since
reducing k by a specific factor will delay the onset of cancer
by the same factor (see [30], where the notation is somewhat
different—a specific factor d is used to highlight this effect).
How realistic are the above figures? For most organisms,
we simply lack the data; for humans, we know more, where
e.g. for females, a 10 cm increase in height has been estimated
to yield a relative risk of 1.14 for all cancers combined [21].
Assuming that the body mass index (mass/height2) remains
unchanged while height increases from 1.65 to 1.75 m, a
10 cm height difference translates into a body size difference
of 12.5%. The 14% increase in cancer risk for a 12.5% increase
in body size may appear to represent a somewhat steeper
relationship than what we have been predicting in figure 2,
but it is important to note that an increase in risk and the pro-
portion of lifespan lost are not directly comparable. This is
because the latter calculation also includes other sources of
mortality. Thus, a 14% higher risk (at each age) will, in rea-
lity, impact lifespan by less than 14%, because other sources
of mortality remain unchanged and will mask some of
cancer’s potential effects.
4. When do we expect selection for improved
cancer defences?
In contrast to the considerations in §3 where k and nwere kept
fixed, cancer defence itself may be an evolving quantity.
Figure 2b depicts the benefits of reducing k by a specified
factor (here exemplified with a 10% reduction), and figure 2c
shows the benefits of increasing n (in this example from n ¼ 3
to n ¼ 4). Comparing figure 2b–c to figure 2a reveals that
increased benefits occur at the same parameter values where
increasing body size is costly in terms of cancer risk. This is
intuitively clear: those situations where further increases of
body size lead to a severe penalty in terms of cancer risk are
also those where reductions in cancer risk can pay off.
In the light of Peto’s paradox, the interpretation of
figure 2b–c is somewhat different, however, from figure 2a.
For simplicity, we go through our argument using reductions
in k as the cancer defence, but similar arguments apply for
increases in n. Large and hence ‘slow’ organisms are located
where N and L are both large. Modest (10%) reductions in k
will here lead to very significant (greater than 10%) increases
in expected reproductively active lifespan, but the same
reduction in k can also yield no benefit when N or L are
small. This is key to understanding why ‘all else will not be
equal’: for the same initial rate k at which cells go through
oncogenetic steps, there are life-histories that create strong
selection to achieve reductions of k, and others where
evolutionary innovations that reduce cancer risk bring
about virtually no benefit. The latter category involves
small-bodied organisms that cannot live long due to extrinsic
mortality; thus better protection against cancer would remain
invisible to selection.
The conclusion, therefore, is that large-bodied organisms
are expected to harbour strong cancer defences, but only if
they are also able to escape other causes of death sufficiently
long such that pushing the likely age of cancer onset towards
older ages has a biologically significant effect on fitness.
It is important to remember that a lower k can be achieved
through two fundamentally different mechanisms. First, as
mentioned in §2, the cell division rate itself can be lower in
an organism of a larger body size. This will automatically
lower k, which is beneficial if all else was equal, but, import-
antly, all else won’t be equal between slow and fast lives. We
do not currently have models that explicitly contrast the
benefit of slow life (dangerously fast replication of cells is
avoided) against the cost (the fitness gains through
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reproduction will now also be gained at a slower pace). In
life-history theory, the magnitude of the detrimental effects
will also depend on the level of extrinsic mortality and also
on the type of population regulation (see [35]).
Even if the details of this argument are best left for further
study (e.g. because cancer cells, once they exist, divide at a
rate that deviates from those in healthy tissue), it is an intri-
guing idea that a sluggish ‘pace of life’ (e.g. low fecundity
per unit time) could be partially an adaptation to keep
cancer risk at bay in large and long-lived organisms (see
also [21]). In the light of cancer biology, such organisms try
to combine what appears difficult: their task is to build a
large body (necessitating many cell divisions) and also main-
tain it for longer than other organisms. This may only be
achievable if the speed of cellular-level activities relating to
growth and reproduction is not excessive, as otherwise
k would be too large to permit long lifespans. It is clearly
of potential relevance for life-history models of the slow–
fast axis, given that being ‘slow’ often evolves despite its
costs (if extrinsic mortality is unchanged, a slow organism
will achieve less reproductive success in its lifetime compared
with faster conspecifics). Explicit models that assume a trade-
off between k and reproductive success per unit time could
shed light on this issue. Given lackof direct evidence this is per-
haps best left an open question, but see [36] for tantalizing
evidence supporting such ideas, in the context of cell growth
rates in cell cultures from short- and long-lived rodents.
Second, any process that protects the organism against
cancer has the effect of lowering k: potential mechanisms
range from improved clearing of infections (many cancers
are known to have infectious causes, e.g. chronic viral hepa-
titis B or C infection can lead to liver cancer) to more efficient
identification and killing of pre-cancer cells [11]. Regardless of
the mechanism, it is important that evolutionary innovations
are often discrete (e.g. extra copies of tumour suppression
genes), and this has consequences for the interpretation of
model results (figure 2) in intra- and interspecific contexts.
Consider, for example, that there is often (but not always
[33]) selection for males to be larger than females. Figure 2a
then predicts that cancer risk may be higher for males than
females. Would males then also evolve stronger defences
against cancer, as figure 2b might predict? The answer is
potentially yes, but with a strong qualifier: if the innovation
is of a discrete kind (e.g. 10% reduction in k) it may be
selected for more strongly in males than in females, but
unless the innovation arises in a sex-limited chromosome, it
is likely to be expressed in both sexes. The entire population
then undergoes a reduction in k, and within a species the
larger cancer risk of larger bodies is still maintained after
the selective sweep.
The interpretation of figure 2 is consequently different for
within- and across-species comparisons. Across species, the
expectation of a stronger reduction in k in organisms with
large N applies. Even so, figure 2b–c only graphs the selective
advantage of employing a mechanism for reducing k or
increasing n, if such a mechanism exists and is not constrained
by other trade-offs. Removing all prospects of cancer is gener-
ally difficult and/or cannot be done without compromising
growth and reproduction (i.e. fitness costs); our figures
assume no such cost of the acting mechanism. If no feasible
mechanism to reduce k or to increase n is at hand, then the
message of figure 2a applies at full strength: further increases
of body size are constrained because the required additional
cell divisions would cause too great a reduction in expected
lifespan, due to cancer.
5. Comparison with other models, model
limitations
Although our model does not yield analytical solutions, its
numerical solutions are accurate—there are ways to consider
the mean and the distribution of the cancer-free lifespan,
and ask how many deaths are due to cancer as opposed to
other causes. This potentially gives added clarity to past
study based on evolutionary simulations [37]. We also
show that it is straightforward to combine body size and
extrinsic mortality in the same model, and that inclusion of
the latter is important for understanding life-history evo-
lution in the face of disease risk, and disease resistance for
different life-history strategies.
Our model treats cell lineages similarly to [27], though we
interpret our N as proportional to the number of cells in the
entire body. Calabrese & Shibata [27] focus on one organ—
the colon—as a colony of stem cells, each dividing at a
constant rate over time, but the initial growth from zygote
to the fixed colony size is not explicitly modelled. Their
focus, however, is not on the quantities we derive, i.e. how
strongly natural selection will favour or disfavour increases
in body size, or reductions in the rate at which rate-limiting
steps occur (i.e. cancer defence).
Nunney [10] takes a somewhat similar approach to deriv-
ing the probability of cancer, but interprets the fitness
consequences in a simpler way than we do. He notes that the
selection coefficient s for preventing a cancer that is lethal
before reproductive age equals p, the incidence of that cancer;
for cancers with later onset age, s, p. Our model differs
from his in that we explicitly consider cancer prevention in
terms of lifespan when cancer can realistically only be delayed,
not indefinitely prevented. Thus, the fitness benefits of a delay
arise, in our model, through a longer career of offspring pro-
duction until death and/or cancer stop(s) this accumulation
of reproductive success. This iswhy it becomes essential to con-
sider other sources of mortality together with the size of the
organism: the effects of these two factors appear equally
strong (figure 2) and they are also expected to covary.
There is also intriguing variability betweenmodels regard-
ingwhether one focuses on the entire organism as one ‘blob’ of
a large number of stem cells, or as a collection of tissues with
independently evolving defences. Nunney [10] focused on
the latter case (while also noting the possibility of controls
that impact all tissues), and found, as expected, that as the
size (number of cells) of a tissue increases, cancer protec-
tion for that tissue should also increase. It is likely to be an
empirical question as to whether baseline protection within
an organism should be affected by tissue specialization in pro-
tection (and vice versa). Recent work by Noble et al. [15]
suggests that different tissue types in humans have different
levels of cancer protection, but these authors could not evaluate
whether this is amplified expression of a given mechanism, or
additional mechanisms.
There is also the question of how the growth and mainten-
ance phase of an organism’s life should be modelled. We
intentionally sidestepped this question, simply noting that
one requires at least N – 1 cell divisions to proceed from a
zygote to an adult individual consisting of N cells. If the initial
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ontological growth is rapid and then followed by a prolonged
maintenance phase where stem cells divide to yield daughter
cells that replace dying cells, the true number of risky divisions
will be higher. The risks related to these two phases are not
necessarily identical [38]. Degregori [38] presented evidence
and arguments indicating that many if not most oncogenic
mutations occur during ontogeny. He argues that increases
in cancer incidence with age (and, therefore, the total cumula-
tive number of stem cell divisions) is due to age-associated
alternations in cells, tissues and their environments that
increase selection for oncogenic events.
Our choice to ignore the problem of ontogeny versus life-
time cell production is probably conservative, in the sense
that we consider the smallest possible difference in the
number of cell divisions between organisms differing in
size. In reality, if large organisms need to first grow large
[10] and then maintain a larger number of cell divisions
throughout life, then the steepness of the surface depicting
costs and benefits in figure 2 is likely to increase.
6. Conclusion and future directions
Our modelling should be considered a first step in integrating
cancer risk with other sources of mortality and the slow–fast
continuum. We hope to have voiced the message that while
cancer biologists should not remain unaware of evolutionary
principles [12,15,30,39], evolutionary ecologists should also
not remain ignorant that multicellular organisms evolve
both life-history traits and cancer protection traits, given
cancer risks (a problem that probably impacts all metazoan
life—see [40] for tumours in Hydra). Importantly, Peto’s para-
dox does not mean that all organisms experience cancer as an
equally important problem. Instead, it highlights that corre-
lations within and across species can be different, despite
both reflecting the same problem: an attempt to grow large
could lead to significantly higher cancer risk, but how
seriously this impacts fitness will also depend in part on
extrinsic mortality.
We encourage more cancer-aware life-history modelling
(see also [39]). As our model is no more than a first step in this
direction, future models could usefully scrutinize the process
of mutation accumulation when organisms first grow and
then, tissue-specifically, maintain a certain body size. It
should also be remembered that organisms differ in whether
they have reached their final size at (or before) maturity; little
appears to be known about cancer in relation to indeterminate
growth, despite the long lives of many of such organisms.
Finally, mathematical models can yield insights into the tem-
poral process of evolution: that is to what extent empirical
patterns are consistent with life history traits and cancer
defences co-evolving, for example in single,matchedalternative
steps, or rathermajor changes in (for example) defence followed
by more continual changes in body size and/or longevity.
Another step towards a cancer-aware life-history theory is
to consider in detail what is required to achieve reproduction
in the context of slow and fast schedules. We have high-
lighted the possibility that a slow pace of life (in any tissue)
could in principle be an adaptation to lower the rate of cell
divisions. But since virtually all steps in processes that lead
to reproductive success are ultimately achieved through
cells dividing, the solution to life’s trade-offs is clearly not
to minimize divisions either. Elucidating the costs and
benefits that build the relevant trade-offs could be the first
steps towards a theory that explains differences in replication
rate across organisms as well as across tissues, including differ-
ences between the sexes. This last point is evolutionarily very
significant, given that males (by definition, sperm-producers)
are a source of much of the mutational load in sexually repro-
ducing populations [41]. Selection for rapid spermatogenesis is
one mechanism that can make males evolve to ‘accept’ higher
cancer risk [42]; thus sexual conflict in species with multiple
matings can involve conflict over how cancer risk is managed,
in addition to many other life-history features [43].
Finally, theory predicts that the force of natural selection
on life-history traits such as body size and on cancer protec-
tion mechanisms will be age-specific [44,45]. Future models
should explore how age-specific extrinsic mortalities (e.g. pre-
dation, disease) and cancer dynamics interact to produce
both life-history and anti-cancer traits [39]. For instance, it
is an empirical fact that cancer incidence increases at older
ages in humans, and the interplay of the cumulative probabil-
ities derived here and the lowered force of selection at
advanced ages [46] merits further attention. It would be inter-
esting to know if this same effect is manifested in life-history
traits such as cell replacement rate (the ‘pace of life’), and
whether selection on early-life performance contributes to
increased incidence in cancers late in life: this would be a
cancer-oriented twist on theories of ageing [45,46]. As these
and other unexplored phenomena are inherently complex,
they will require mathematical models to yield empirically
testable predictions.
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